U.S. SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): February 2, 2004
COMMISSION FILE NUMBER: 000-32141
Nutra Pharma Corp.
----------------------------------------------------
(Exact name of registrant as specified in its charter)
California 91-2021600
----------------------------------------- -------------------------
(State or jurisdiction of incorporation (I.R.S. Employer I.D. No.)
or organization
4001 NW 73rd Way
Coral Springs, Florida 33065
------------------------------------------ ----------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number: (954) 509-0911
485 Martin Lane, Beverly Hills, CA 90210
---------------------------------------------------------
(Former name or former address, if changed since last report)
Item 4. Changes in Registrant's Certifying Accountant
On February 2, 2004, the Registrant was informed that it(s current independent
accountant, Rogelio G. Castro, had resigned as the principal accountant to
audit the Registrant(s financial statements. The independent accountant(s
report on the financial statements for the Registrant over the past two years
has not contained an adverse opinion or a disclaimer of opinion, nor was it
qualified or modified as to uncertainty, audit scope, or accounting principles,
except for the fact that the accountant, in his report for the past two fiscal
years has included an opinion that, due to the Registrant(s lack of revenue
producing assets and history of losses, there is doubt about the Registrant(s
ability to continue as a going concern.
During the two most recent fiscal years and the interim period preceding the
resignation, there have been no disagreements with the former accountant on any
matter of accounting principles or practices, financial statement disclosure,
1
or auditing scope or procedure, which disagreements, if not resolved to the
satisfaction of the former accountant, would have caused it to make reference
to the subject matter of the disagreements in connection with the reports.
No new independent accountant has yet been appointed.
SIGNATURES
------------
Pursuant to the requirements of the Securities Act of 1934, the Registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
Dated: February 9, 2004
Nutra Pharma Corp.
By: Rik Deitsch
---------------------------
Rik Deitsch
Chief Executive Officer
And Chief Financial Officer
CERTIFICATION
--------------
In connection with the current report of Nutra Pharma Corp. (the (Company() on
Form 8K for February 9, 2004, as filed with the Securities and Exchange
Commission on the date hereof, Rik Deitsch certifies, pursuant to 18 U.S.C.
Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of
2002, that to the best of their knowledge:
1. The report fully complies with the requirements of Section 13(a) or 15(d)
of the Securities Exchange Act of 1934; and
2. The information contained in the report fairly presents, in all material
respects, the financial condition and results of the Company.
Dated: February 9, 2004 By: Rik Deitsch
------------------------------
Chief Executive Officer,
And Chief Financial Officer
2